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Background: Suspected adverse events (AE) after 
human papillomavirus (HPV) vaccines include postural 
orthostatic tachycardia syndrome (POTS), chronic 
fatigue syndrome (CFS), complex regional pain syn-
drome (CRPS) and symptoms including headache and 
orthostatic intolerance. Aim: We aimed to identify phe-
notypes of AEs after HPV vaccination, defined as pat-
terns of AE terms (signs, symptoms, diagnoses), and 
to evaluate if identified phenotypes reflected previ-
ously suspected symptomatology or heightened pub-
lic concerns over HPV vaccine safety since 1 January 
2015. Methods: We conducted a retrospective obser-
vational study using latent class cluster analysis of all 
serious AE reports (n = 963) reported by females resid-
ing in Denmark between September 2009 and August 
2017. Resulting clusters were characterised accord-
ing to AE terms associated with POTS, CFS and CRPS 
before (September 2009–December 2014) and dur-
ing (January 2015–August 2017) a time of heightened 
media activity regarding HPV vaccines. Results: Four 
clusters of AE reports were distinguished. The most 
common symptoms were fatigue, dizziness and head-
ache but their frequency varied among clusters. The 
majority of reports in one cluster were submitted dur-
ing a period of heightened media activity, including an 
anomalous spike in submissions in December 2015; a 
high proportion of these reports included the symp-
toms cognitive disorder (78%), abdominal pain (77%), 
dysuria (60%) and sleep disorder (60%). Conclusions:
Non-specific symptoms including headache, fatigue 
and dizziness feature prominently in serious AE 
reports from females in Denmark. Our analysis identi-
fied a cluster of reports, likely media stimulated, with 
a focus on symptoms of CFS and POTS.
Introduction
In 2006, Gardasil – a quadrivalent human papilloma-
virus (HPV) vaccine targeting HPV types 6, 11, 16 and 
18, was first licenced in the European Union. A bivalent 
vaccine (Cervarix) targeting HPV types 16 and 18 was 
subsequently licenced in 2007 and a nonavalent vac-
cine (Gardasil-9) in 2015. In Denmark, there has been a 
catch-up programme for HPV vaccination for girls aged 
13–15 years since 1 October 2008. From 1 January 2009, 
HPV vaccination was included as part of the national 
childhood vaccination programme for girls aged 12 
years. HPV catch-up programmes ran from 27 August 
2012 to 31 December 2013 for women born 1985–92 
and from 1 January 2014 to 31 December 2015 for those 
born 1993–97 [1,2]. Gardasil was used in programmes 
until February 2016 when Cervarix was phased in and 
until November 2017, when Gardasil-9 was introduced 
replacing Cervarix [3,4].
The World Health Organization (WHO) has recom-
mended implementation of HPV vaccination pro-
grammes worldwide [5], however, public concern 
regarding adverse reactions to the vaccines have 
threatened their successful introduction in some coun-
tries. For example, the Ministry of Health, Labour and 
Welfare in Japan has withdrawn its recommendation for 
vaccination due to fears of adverse events (AE) [6]. The 
uptake of the HPV vaccine in Denmark fell sharply fol-
lowing the broadcasting of a documentary about HPV 
vaccine AEs, ‘De vaccinerede piger’ (The vaccinated 
girls) in March 2015. HPV vaccine uptake remained low 
until September 2016, by which time only 41% of girls 
born in 2003 (due to receive first dose of the vaccine at 
12 years) had received the vaccine [7].
In 2013, a case series reported six patients with onset 
of postural orthostatic tachycardia syndrome (POTS) 6 
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days–2 months following HPV vaccination [8]. In 2015, 
a case series from a Danish syncope clinic described 
patients investigated for suspected autonomic dys-
function after HPV vaccination [9]; symptoms of head-
ache, orthostatic intolerance, fatigue or nausea were 
reported frequently but not all patients met a diagno-
sis of POTS. An additional case series from the Danish 
syncope clinic, described 35 patients diagnosed with 
chronic fatigue syndrome (CFS) after HPV vaccination 
[10]. Co-diagnosis of POTS in patients with CFS (range 
13–27%) is recognised [11,12] and is likely due to chronic 
fatigue being a common presenting feature of POTS. In 
Japan, a case series of 40 female patients aged 11–17 
years old described symptoms including headaches, 
general fatigue and limb pain after HPV vaccination – 
chronic regional pain syndrome (CRPS) was diagnosed 
in 18 patients and POTS in four patients including three 
with both diagnoses [13]. However, these studies have 
not been supported by more comprehensive studies, 
such as a nationwide cohort study from Norway, which 
found no association between HPV vaccination and 
increased risk of CFS, and a study from the United 
Kingdom (UK) utilising AE reports, which also found no 
association [14,15]. A study of AE reports in the Vaccine 
Adverse Event Reporting System (VAERS) found approx-
imately one case of POTS per 6.5 million HPV vaccine 
doses distributed in the United States (US) [16].
In September 2013, the Danish authorities raised the 
POTS signal to the European Medicines Agency (EMA). 
In November 2015, the EMA concluded in its report 
that the current evidence did not support a causal link 
between HPV vaccination and POTS, CRPS or CFS [17]. 
The EMA also noted that most of the reports of POTS 
came from the same Danish syncope clinic [9,10]. The 
documentary ‘De vaccinerede piger’ in March 2015, the 
EMA report in November 2015 and attendant media 
coverage of both stimulated public concern and may 
Table 1
Characteristics of reports of serious adverse events in females following human papillomavirus vaccination, stratified by age 
at vaccination, Denmark, 12 September 2009–17 July 2017 (n = 963)
Characteristics Total 12 September 2009–31 December 2014 1 January 2015–17 July 2017
Number of serious AE reports
All reports 963 305 658
11–17 years 525 130 395
≥ 18  years 403 165 238
Unknown age 35 10 25
Median age at vaccination in years (IQR)
All reports 15.1 (12.5–24.4) 21.1 (12.8–26.4) 14.5 (12.4–23.2)
11–17 years 12.6 (12.1–14.1) 12.6 (12.2–14.0) 12.6 (12.1–14.1)
≥ 18 years 25.4 (22.2–31.5) 25.9 (22.5–31.5) 24.9 (22.0–31.6)
Median age at report submission in years (IQR)
All reports 21.8 (17.1–27.1) 22.8 (16.3–27.9) 21.4 (17.6–26.7)
11–17 years (at vaccination) 17.7 (15.4–20.2) 15.5 (13.8–17.9) 18.4 (16.1–20.8)
≥ 18 years (at vaccination) 27.9 (25.3–33.5) 27.2 (24.2–32.3) 28.3 (26.1–34.8)
Median time from vaccination to AE term onset in days (IQR)
All reports 191 (36–508) 85 (12–297) 223 (58–615)
11–17 years 263 (56–714) 203 (44–479) 292 (67–812)
≥ 18 years 135 (22–333) 63 (5–212) 183 (55–420)
Median time from AE term onset to report submission in days (IQR)
All reports 785 (321–1,471) 306 (113–728) 973 (601–1,774)
11–17 years 1,131 (472–1,873) 674 (201–1,530) 1,265 (630–2,043)
≥ 18 years 601 (207–951) 216 (73–436) 844 (579–1,140)
Median time from vaccination to report submission in days (IQR)
All reports 1,231 (713–2,162) 477 (207–1,142) 1,562 (1,018–2,364)
11–17 years 1,798 (1,052–2,379) 1,059 (350–1,670) 2,162 (1,336–2,473)
≥ 18 years 897 (399–1,212) 352 (174–594) 1,082 (899–1,399)
Median number of AE terms per report (IQR)
All reports 13 (6–22) 9 (4–23) 14 (7–22)
11–17 years 12 (5–22) 10 (3–23) 13 (6–21)
≥ 18 years 14 (6–23) 9 (4–23) 15 (9–24)
AE: adverse event; IQR: interquartile range.
Ages used to stratify are the ages at the time of vaccination.
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have influenced AE reports. A study by Chandler et al. 
using HPV vaccine AE reports excluded those submit-
ted after 1 January 2015 to reduce the effect of media 
stimulated reporting and found that the AE terms head-
ache, dizziness and fatigue or syncope tended to clus-
ter together [18].
In Denmark, patients and third parties including health-
care professionals and the Patient Compensation 
Association can report AEs following drug use or vac-
cination to the Danish Medicines Agency (DMA) via an 
online form [19]. The DMA keeps a nationwide database 
of these reports. Each entry in this database includes 
information on: (i) the suspected vaccine, (ii) the expe-
rienced symptoms, signs and diagnoses coded into 
AE terms using the Medical Dictionary for Regulatory 
Activities (MedDRA) at the ‘Preferred Term’ level, (iii) 
self-reported date of exposure, (iv) self-reported date 
of onset for each AE term, (v) date of report submis-
sion, (vi) the reporter qualification (including physician, 
nurse, lawyer and consumer or other non-healthcare 
professional) and, (vii) the identity of the patient using 
a unique identification number used in all other Danish 
nationwide registers. The DMA classifies AE reports as 
serious based on fulfilling one of the following crite-
ria: fatal, life-threatening, hospitalisation, disability/
incapacity from employment or education, congeni-
tal abnormality, or other medically significant events 
including cases of suspected POTS or two or more 
syncopal episodes due to their relevance to a putative 
safety signal.
This study used reports of serious AE following HPV 
vaccination submitted to the DMA from females aged 
5 years and older residing in Denmark. The aim of this 
study was to identify and describe adverse reaction 
Figure 1
Submission dates of reports of serious adverse events to human papillomavirus vaccination in females, Denmark, January 
2013–July 2017 (n = 919)
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phenotypes, defined as patterns of AE terms reported 
to the DMA in serious AE reports following HPV vac-
cination using latent class cluster analysis. We aimed 
to evaluate if the previously characterised symptoma-
tology figured prominently in the identified clusters 
and whether the identified clusters related to height-
ened public concerns over HPV vaccine safety since 1 
January 2015.
Methods
A retrospective observational study of adverse 
event reports
In August 2017, Statens Serum Institut obtained a data-
set comprising all serious AE reports after HPV vacci-
nation submitted to the DMA between 12 September 
2009 and 17 July 2017 (the first and last reported AE, 
respectively). A total of 979 unique serious AE reports 
following HPV vaccination were reported by 976 indi-
viduals. The collection of all AE terms reported for one 
individual relating to one vaccination event constituted 
one report (see  Supplement S1). AE terms consisted 
primarily of symptoms rather than specific diagnoses. 
The dataset did not include the reason for each AE 
report’s classification as serious, but previous studies 
on the safety profile of HPV vaccines in Denmark found 
that 17% of reports were from patients whose normal 
daily activities were impaired following HPV vaccina-
tion [20,21].
These reports comprised 28,465 AEs (1,164 unique AE 
terms). We removed duplicates where multiple persons 
with different reporter qualifications (e.g. physician 
and lawyer) reported the same patient and AE terms. 
We also removed reports from individuals younger 
than 5 years of age (who were children of women vacci-
nated in pregnancy) and reports from males. The final 
resulting dataset consisted of 963 reports from 960 
females reporting 15,949 AEs (1,144 unique AE terms). 
The reports included 864 AE reports for Gardasil, two 
AE reports for Cervarix and 97 AE reports where the 
type of HPV vaccine was unspecified.
Of 963 reports, the date of vaccination was incomplete 
in 65 (7%), 24 only contained month and year, 17 only 
contained year and 24 had completely missing dates. 
Danish civil registration numbers i.e. unique personal 
identification numbers for Danish residents, were used 
in individual AE reports and are also used in all Danish 
administrative databases [22]. It was possible there-
fore, to link the submitted AE reports via this identi-
fication number with the Danish Vaccination Registry 
[23] to obtain a more accurate date of HPV vaccination 
recorded at the time of vaccination that is not limited 
by recall error.
Of 15,949 reported AEs, the date of AE onset was incom-
plete for 11,968 AE terms (75%), 3,144 contained year 
and month of onset, 2,948 only contained the year and 
5,876 had no date at all. We used the date information 
to estimate time since HPV vaccination to AE term onset 
Table 2
Ten most common adverse event (AE) terms within clusters of reports of serious AE following human papillomavirus 
vaccination in females, Denmark, 12 September 2009–17 July 2017 (n = 963)
Rank
Cluster 1 (120 reports) Cluster 2 (130 reports) Cluster 3 (329 reports) Cluster 4 (384 reports)
AE term n % AE term n % AE term n % AE term n %
1 Fatigue 114 95 Fatigue 120 92 Fatigue 294 89 Headache 142 37
2 Dizziness 113 94 Dizziness 118 91 Dizziness 248 75 Fatigue 126 33
3 Headache 107 89 Headache 111 85 Headache 242 74 Dizziness 104 27
4 Nausea 101 84 Cognitive disorder 102 78 Nausea 186 57 Syncope 71 18
5 Arthralgia 100 83 Abdominal pain 100 77 Arthralgia 149 45 Nausea 53 14
6 Disturbance in attention 99 83 Nausea 98 75
Disturbance in 
attention 143 43 Arthralgia 47 12
7 Memory impairment 88 73
Muscular 
weakness 94 72 Abdominal pain 118 36
Disturbance in 
attention 35 9
8 Muscular weakness 80 67 Palpitations 92 71 Syncope 110 33
Sensory 
disturbance (tied 
with 9)
34 9
9 Myalgia 75 63 Dysuria (tied with 10) 78 60 Muscular weakness 101 31
Abdominal pain 
(tied with 8) 34 9
10 Palpitations 73 61
Sleep 
disorder (tied 
with 9)
78 60 Myalgia/memory impairmenta 100 30
Paraesthesia/ 
pain/migrainea 26 7
AE: adverse event.
a There was a tie between the listed adverse event terms.
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and to AE report submission date. We performed date 
imputation, as performing calculations with only com-
plete AE term onset dates would underestimate time 
from vaccination to AE term onset and/or time from 
AE term onset to report submission (Supplement S1). 
Completely missing AE term onset dates were excluded 
from date calculations, but these reports were still 
used for cluster analysis as date information was not 
required.
Cluster analysis
We used latent class cluster analysis to estimate clus-
ters (‘latent classes’) of AE reports. Latent class cluster 
analysis differs from classical clustering methods by 
being a model-based approach, with the assumption 
that the observed data has been generated by a mix-
ture of probability distributions [24]. For a pre-spec-
ified number of clusters our model assumes that the 
reports are independent, that each report is assigned 
to a cluster with some probability and that the AE 
terms are Bernoulli distributed and are conditionally 
independent within the clusters. The model parame-
ters estimated are the probability of a report belonging 
to a certain cluster and the conditional probabilities of 
each AE term given the cluster using maximum likeli-
hood methods (applying the expectation maximization 
algorithm combined with the Newton-Raphson method 
[25]).
A requirement of the model is that the number of 
clusters and AE terms included in the model must 
be balanced against the number of reports in the 
dataset; using  m  clusters and  k  AE terms requires at 
least m*k + m-1  reports. In our dataset, many AE terms 
were only present in a few reports, with 857 (75%) of 
unique AE terms being present in five or fewer reports.
We selected the optimal number of clusters based on 
the Bayesian information criteria (BIC) [26], and used 
200 iterations (each with a random initial value for the 
expectation maximization algorithm) for each combi-
nation of clusters and AE terms to reduce the risk of 
choosing a local solution to the log-likelihood. We ini-
tially performed an analysis with the 48 most frequent 
symptoms in our dataset, fitting from 1 to 20 clus-
ters. After finding the optimal number of clusters for 
the 48 most frequent AE terms, we steadily increased 
the amount of AE terms included in the analysis. The 
purpose of this was to use as much of the dataset as 
possible and to evaluate the stability of the cluster 
analysis if we omitted less frequent AE terms. The final 
model included four clusters and 192 AE terms.
All cluster analyses were conducted in the program-
ming language R (R Foundation for Statistical comput-
ing, Vienna, Austria) using the poLCA package for the 
cluster analysis [27,28].
Cluster characterisation
To evaluate the similarity of the resulting clusters with 
POTS, CRPS and CFS, we selected associated terms 
from current diagnostic guidelines specific to each 
syndrome (respectively, the ‘consensus statement’ on 
POTS [29], the ‘Budapest’ criteria for CRPS [30] and 
the Institute of Medicine (IOM) CFS diagnostic criteria 
[31]). IOM has proposed the use of the term ‘systemic 
exertional intolerance syndrome’ to replace CFS, but as 
our data was coded using the term ‘chronic fatigue syn-
drome’ we used this terminology.
The selected POTS terms were ‘postural orthostatic 
tachycardia syndrome’, ‘orthostatic intolerance’, ‘tach-
ycardia’, ‘palpitations’ and ‘syncope’. The selected 
CRPS terms were ‘complex regional pain syndrome’, 
‘hyperaesthesia’, ‘allodynia’, ‘arthralgia’, ‘muscular 
Table 3
Features of POTS, CFS and CRPS in clusters formed from serious adverse event reports following human papillomavirus 
vaccination in females, Denmark, 12 September 2009–17 July 2017 (n = 963)
Features
Cluster 1 
 
(120 reports)
Cluster 2 
 
(130 reports)
Cluster 3 
 
(329 reports)
Cluster 4 
 
(384 reports)
n (IQR) % n (IQR) % n (IQR) % n (IQR) %
AE terms per report, median 42 (37–53) NA 20 (17–25) NA 16 (12–21) NA 5 (3–7) NA
Reports containing POTS 36 30 34 26 55 17 15 4
Reports containing CRPS 1 1 0 0 4 1 1 0
Reports containing CFS 5 4 0 0 4 1 2 1
POTS-associated terms per report, median 1 (1–2) NA 1 (1–2) NA 1 (0–1) NA 0 (0–1) NA
CRPS-associated terms per report, median 2 (1–3) NA 1 (1–2) NA 1 (0–1) NA 0 (0–0) NA
CFS-associated terms per report, median 2 (1–2) NA 2 (1–3) NA 1 (1–2) NA 0 (0–1) NA
Reports containing headache, 
dizziness and either syncope or fatigue 98 82 99 76 181 55 39 10
AE: adverse event; CFS: chronic fatigue syndrome; CRPS: chronic regional pain syndrome; IQR: interquartile range; NA: not applicable; POTS: 
postural orthostatic tachycardia syndrome.
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weakness’ and ‘hyperhidrosis’. The selected CFS terms 
were ‘chronic fatigue syndrome’, ‘fatigue’, ‘malaise’, 
‘sleep disorder’ and ‘impaired work ability’. The fre-
quency of these terms was compared with the total 
number of AE terms per report to identify clusters 
which represented phenotypes similar to those syn-
dromes, independent of diagnosis. We also com-
pared the frequency of the combination of the terms 
headache, dizziness and either fatigue or syncope 
(previously suggested to be representative of an auto-
nomic dysfunction syndrome [18]) in reports to inves-
tigate whether this phenotype was represented in our 
clusters.
Results
Ages of females reporting serious AEs after 
HPV vaccination
The median age at HPV vaccination of female patients 
reporting serious AEs to the DMA was 15.1 years (Table 
1). The age at vaccination was bimodally distributed, 
with a large peak at 12 years reflecting those vac-
cinated in the childhood programme and a smaller 
peak at 21 years reflecting those vaccinated as part 
of the catch-up programmes and by private purchase. 
The median age at report submission was 21.8 years, 
which is 6.7 years after the median age at vaccination. 
However, this apparent large time lag is to some extent 
caused by the bimodal distribution of both features. 
Comparing the period before 1 January 2015 against 
the period after, we observed a decrease in median 
age at vaccination from 21.1 to 14.5 years, reflecting 
the increasing number of adolescent girls vaccinated 
through the national childhood programme, compared 
with fewer adult women being vaccinated through the 
catch-up programme, which ended in 2015.
Temporal features of reports
Median time from vaccination to AE term onset was 191 
days and median time from vaccination to report sub-
mission was 1,231 days. For reports submitted from 12 
September 2009 to 31 December 2014 the median time 
from vaccination to AE term onset increased from 85 
days to 223 days. In total, 305 reports were submitted 
of which, 139 were between July and December 2013. 
For reports submitted after 1 January 2015, the median 
time from vaccination to report submission increased 
from 477 days to 1,562 days (Table 1). The total number 
of reports filed was 658, with an anomalous spike com-
prising 64 reports during a single week in December 
2015 (Figure 1). 
Cluster analysis results and characterisation
The cluster analysis identified four clusters of AE 
reports. All clusters had fatigue, dizziness and head-
ache as the most common AE terms, while three clus-
ters (1, 2, 3) had these terms in the majority (> 50%) of 
reports (Table 2).
Cluster 1 had 120 reports, with high proportions of 
fatigue (95%), dizziness (94%) and headache (89%) 
(Table 2). It had a median of 42 AE terms per report, 
which was the greatest of the four clusters and also 
had the greatest proportion of reports containing the 
AE terms ‘POTS’ (30%), and ‘CFS’ (4%) and ‘CRPS’ (1%) 
(Table 3). Reports contained a median of one POTS-
associated AE term, two CRPS-associated AE terms and 
two CFS-associated AE terms (Table 3). Of 120 reports, 
the combination of headache, dizziness and syncope 
or fatigue featured in 82% of reports. Cluster 1 also 
had the oldest median age at vaccination (19.8 years; 
IQR: 12.8–26.0) (Table 4).
Table 4
Temporal features of clusters of reports of serious adverse events following human papillomavirus vaccination in females, 
Denmark, 12 September 2009–17 July 2017 (n = 963)
Temporal features
Cluster 1 
 
(120 reports)
Cluster 2 
 
(130 reports)
Cluster 3 
 
(329 reports)
Cluster 4 
 
(384 reports)
n (IQR) % n (IQR) % n (IQR) % n (IQR) %
Reports 12 September 2009–31 December 2014 53 44 6 5 82 25 164 43
Reports 1 January 2015–17 July 2017 67 56 124 95 247 75 220 57
Median age at vaccination (years) 19.8 (12.8–26.0) NA
16.3 
(12.6–23.7) NA
15.3 
(12.5–24.1) NA
14.2 
(12.4–23.9) NA
Median age at report submission (years) 24.1 (18.5–28.8) NA
23.5 
(18.7–28.0) NA
21.9 
(17.7–27.2) NA
20.2 
(16.3–26.6) NA
Median time from vaccination to AE onset, 
(days) 187 (27–444) NA 172 (27–417) NA 203 (43–610) NA 194 (48–432) NA
Median time from AE term onset to report 
submission (days)
713 
(264–1,516) NA
1,032 
(616–1,959) NA
856 
(390–1,463) NA
670 
(191–1,296) NA
Median time from vaccination to report 
submission (days)
1,063 
(627–2,079) NA
1,553 
(1,156–2,473) NA
1,322 
(873–2,238) NA
1,022 
(380–1,798) NA
AE: adverse events; IQR: interquartile range; NA: not applicable.
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Figure 2
Number of AE terms associated with POTS, CRPS and CFS relative to total number of AE terms in reports of serious AE 
following HPV vaccination in females, Denmark, 12 September 2009–17 July 2017 (n = 963)
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Cluster 2 had 130 reports, also with high proportions 
of fatigue (92%), dizziness (91%) and headache (85%), 
but differed from the other clusters by high proportions 
of cognitive disorder (78%), abdominal pain (77%), dys-
uria (60%) and sleep disorder (60%) (Table 2). It also 
had a high proportion of AE reports containing POTS 
(26%) (Table 3). Although cluster 2 had no reports with 
the AE term ‘CFS’, it had a median of two other AE terms 
considered CFS-associated, which was high relative to 
the other clusters. Of 130 reports, the combination of 
headache, dizziness and syncope or fatigue featured in 
76% of reports. This cluster had the shortest median 
period from vaccination to AE term onset at 172 days, 
but the longest median period from AE term onset to 
report submission at 1,032 days (Table 4). The majority 
of reports in this cluster (95%) were submitted after 1 
January 2015.
Cluster 3 had 329 reports, with a high proportion of 
reports with fatigue (89%), dizziness (75%), headache 
(74%) and nausea (57%), but other terms were reported 
relatively inconsistently with less than 50% each (Table 
2). It had a median number of 16 AE terms per report 
and the combination of headache, dizziness and syn-
cope or fatigue featured in 55% of reports (Table 3). 
Although there were 55 reports with POTS, four with 
CRPS and four with CFS (one report featured both POTS 
and CFS), these only accounted for 19% of reports.
Cluster 4 had 384 reports, with headache (37%), 
fatigue (33%) and dizziness (27%) as the most com-
mon AE terms although these proportions were low 
compared to other clusters (Table 2). Sensory distur-
bance and paraesthesia ranked higher in this cluster 
compared with other clusters, but were still relatively 
rare at 9% and 7%, respectively. It had a median of five 
AE terms per report, and only 5% of reports contained 
POTS, CRPS or CFS, while 10% had the combination 
headache, dizziness and syncope or fatigue (Table 3).
The submission dates of AE reports for clusters 1, 3 
and 4 tended to follow a similar temporal pattern, but 
reporting of AE in cluster 2 was more prominent after 
1 January 2015 and was primarily responsible for the 
anomalous spike in December 2015 with 45 reports 
(35% of all cluster 2 reports) (Figure 1). Comparing 
the number of AE terms per report to number of POTS, 
CFS and CRPS associated terms did not distinguish 
any close relationship between clusters and selected 
terms. They visually demonstrated that one of the main 
features separating the four clusters was the number of 
AE terms per report, except a close overlap of cluster 2 
and 3 (Figure 2). 
Discussion
In our study, fatigue, headache and dizziness were the 
most common AE terms identified in all four clusters 
of AE reports, particularly in clusters 1–3; this combi-
nation was found in 417 (43%) serious AE reports in 
our study. A study by Chandler et al. found a similar 
combination of symptoms i.e. headache, dizziness and 
fatigue or syncope [18] and a study monitoring quad-
rivalent HPV vaccines in the VAERS also found that 
fatigue, headache and dizziness were among the most 
common AE terms reported from females in the US [32].
Temporal analysis revealed a clear pattern in report 
submission dates with peaks in 2013 and 2015; both 
periods coincided with heightened media activity 
regarding HPV vaccine safety in Denmark, which may 
have increased reporting of AE. As well as the 2015 
documentary about HPV vaccine AE, there were two 
series of Danish newspaper articles with negative 
views on HPV vaccination in 2013, which in a study by 
Suppli et al. were correlated with the decline in HPV 
vaccine uptake at that time [33]. We also found that 
cluster 2 consisted mainly of reports submitted after 1 
January 2015 and characterised a prominent temporal 
anomaly, with a relatively large number of reports sub-
mitted during a single week in December 2015.
Changes in diagnostic criteria may also be a contribu-
tory explanation for the majority of reports in cluster 2 
being submitted since 2015. In 2015, IOM revised the 
diagnostic criteria for CFS, describing ‘cognitive impair-
ment’ and ‘sleep disorder’ as core symptoms, with 
genitourinary and gastrointestinal symptoms (such as 
dysuria and abdominal pain) as secondary symptoms 
[31]. We note that in addition to fatigue, all these symp-
toms are common in cluster 2.
In order to identify phenotypes of AE reports without 
explicit diagnoses, we used a selection of AE terms 
closely associated with POTS, CRPS and CFS, based 
on current diagnostic guidelines. We selected AE terms 
specific to each syndrome, however, the inherent non-
specific nature of these syndromes weakens the dis-
criminatory ability of the selected AE terms for these 
case definitions. For example, fatigue, while essential 
to CFS, features in many illnesses which would require 
exclusion before a diagnosis of CFS can be made.
Caution is warranted in the interpretation of sponta-
neous AE reports, especially following the introduc-
tion of a new vaccine into a population. From public 
health surveys we know that a non-trivial proportion 
of adolescent girls will experience symptoms shortly 
after vaccination due to chance alone [34]. In addition, 
the majority of reported symptoms e.g. headaches, 
dizziness etc. are not uncommon in adolescents. In a 
large health survey of Danish schoolchildren, 30% of 
all girls aged 13 years experienced headaches, 20% 
reported dizziness, 46% sleep disorder and 20% stom-
ach aches on a weekly basis [35]. The results from that 
survey, suggest that the symptomatology of these girls 
is similar to that found in our AE data following HPV 
vaccination. Observational studies of HPV AE have not 
substantiated any association with CFS, while studies 
in Norway and Finland have documented an increase in 
the occurrence of CFS which occurred independently of 
HPV vaccination [14,15,36].
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This study had several limitations. First, we used data 
from spontaneous reports specifically when determin-
ing the exact date of AE term onset, which was often 
missing. This, together with the delay between vacci-
nation date to the date of AE report submission in the 
majority of reports, prevents the identification of a rel-
evant latency period between vaccination and AE onset 
and weakens any potential safety signal that might be 
implied. However, the incomplete date information did 
not impact the validity of the results as date informa-
tion was not used in the cluster analysis. AE report 
narratives and medical records were not available 
for review; therefore, we were unable to validate AE 
reports independently.
Second, the cluster analysis method used restricted 
the number of AE terms and clusters allowed. While our 
results remained robust when excluding more AE terms 
than dictated by the total number of reports available 
for analysis, it is possible that we did not identify small 
clusters characterised by rare AE terms.
Finally, we were unable to analyse by vaccine type, this 
was due to the large number of reports with unspeci-
fied HPV vaccine type and the requirement of the clus-
tering method. However, the majority of vaccine types 
reported were Gardasil and as the Danish vaccination 
programme used Gardasil exclusively until February 
2016, it can be assumed that the majority of unspeci-
fied vaccine types were Gardasil.
Conclusion
In our study, cluster analysis identified a group of 
AE reports (cluster 2) likely resulting from stimulated 
reporting due to increased focus on symptoms of CFS 
and POTS in the clinical setting and in the media. 
Headache, dizziness and fatigue were prominent fea-
tures of all four clusters identified from AE reports 
following HPV vaccination of girls and young women. 
These are mainly non-specific symptoms and are com-
mon occurrences in the target population, so the cau-
sation of these symptoms by the HPV vaccine cannot 
be confirmed by this analysis. We found little support 
for clusters representing CFS or CRPS, nor any novel 
autonomic dysfunction syndrome; POTS featured 
explicitly in many reports in clusters 1–3 (17–30%), but 
to an extent compatible with the fact that the DMA has 
specifically designated reports of POTS as serious AEs.
This study indicates the utility of cluster analysis in 
identifying groups of reports that may relate to stim-
ulated reporting and specific diagnostic practices. 
Cluster analysis is a relatively new method in epidemi-
ology and further validation and advancement of this 
technique is warranted. Spontaneous reporting sys-
tems and the interpretation of safety signals can be 
improved with greater validation of details of reports 
such as vaccine type and onset of AEs, and further 
understanding of the relationship between reporting 
patterns and media activity.
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